CEO Executive AssistantHealthcare organizations are subject to regulatory review from multiple agencies simultaneously: CMS, the OIG, state health departments, DEA, FTC, and state professional licensing boards, among others. Each regulatory relationship has its own jurisdiction, authority, and enforcement mechanisms. Managing regulatory relationships and responding to regulatory reviews requires specialized expertise and coordinated organizational response.
A regulatory review delegation playbook clarifies who leads regulatory response, how the CEO is engaged, and how the organization maintains an organized, consistent approach across multiple regulatory relationships.
The Regulatory Landscape
Healthcare regulatory oversight is multidimensional:
CMS. Oversees Medicare and Medicaid certification, billing compliance, and conditions of participation.
Office of Inspector General. Investigates fraud, waste, and abuse in federal healthcare programs through audits, reviews, and enforcement actions.
State Health Departments. License facilities and providers, conduct annual surveys, and investigate complaints.
DEA. Regulates controlled substance prescribing and dispensing.
FTC. Reviews healthcare mergers for antitrust implications.
State AG offices. May investigate billing practices, charitable asset use (for nonprofits), or other healthcare practices with consumer protection implications.
Accreditation bodies. Joint Commission, DNV, and other accreditors conduct surveys that have regulatory equivalence for Medicare certification.
Regulatory Response Leadership
Chief Compliance Officer. The CCO is the primary organizational leader for regulatory relationships and review response. The CCO manages ongoing regulatory monitoring, leads responses to audits and investigations (in coordination with legal counsel), and reports regulatory risk to the CEO and board.
General Counsel. The GC provides legal strategy for regulatory response, manages attorney-client privilege issues, and coordinates with outside counsel for significant regulatory matters.
CFO. For financial and billing-related regulatory reviews (RAC audits, CMS billing audits), the CFO and revenue cycle leadership work alongside the CCO.
CMO/CNO. For clinical care-related regulatory reviews (conditions of participation surveys, state inspections), the CMO and CNO provide clinical leadership for the response.
Routine Regulatory Reviews: Fully Delegated
Most routine regulatory interactions belong entirely to the compliance, legal, and operational teams:
- Annual state health department license renewals
- Medicare cost report reviews
- RAC and MAC claim audits
- Routine accreditation surveys
- Professional licensing renewals for staff
The CEO is not involved in managing these processes. The CCO and relevant operational leaders handle them with routine reporting to the CEO as part of compliance program updates.
Significant Regulatory Reviews: CEO Engagement Required
Some regulatory reviews require CEO engagement due to their potential impact:
OIG investigations. Any contact from the OIG or DOJ regarding healthcare fraud and abuse should immediately involve the CCO and GC, with CEO notification. The potential consequences of an OIG investigation (civil monetary penalties, exclusion from federal programs) can be existential.
CMS conditions of participation jeopardy. When CMS notifies a hospital that its conditions of participation are in jeopardy, the CEO must be directly engaged in the response. CoP jeopardy can result in termination of Medicare certification.
State health department enforcement actions. Civil monetary penalties, license suspension threats, or plan of correction requirements for significant deficiencies require CEO engagement.
Antitrust review. For mergers and acquisitions subject to FTC review, the CEO is involved in strategic decisions about transaction structure and responses to regulator questions.
For how regulatory delegation connects to compliance governance, the healthcare CEO delegation framework provides context.
The Self-Disclosure Protocol
When the organization identifies a potential regulatory violation, self-disclosure to the relevant regulatory agency may be legally and strategically appropriate. CMS, OIG, and various state agencies have self-disclosure protocols that typically provide more favorable resolution terms than violations discovered through external investigation.
The decision to self-disclose is a CEO and GC-level decision with board awareness. The CCO and GC should present the facts, legal analysis, and disclosure recommendation to the CEO, who makes the final decision in consultation with the board.
Self-disclosure decisions must never be made by compliance or legal staff without CEO and board engagement.
Board Reporting on Regulatory Matters
The board’s compliance and audit committee should receive regular reporting on regulatory matters: pending audits, significant enforcement actions, self-disclosure decisions, and compliance program metrics. The CEO and CCO should jointly present significant regulatory developments to the board.
The CEO must ensure the board is not surprised by significant regulatory matters. Early disclosure to the board, including when the situation is still developing, builds governance trust and ensures the board is prepared to provide appropriate oversight.
Training for Regulatory Review Events
When a regulatory agency arrives for a survey or investigation, organizational staff interact with regulators in ways that can significantly affect the regulatory outcome. Staff who are trained to respond professionally, accurately, and in compliance with legal guidance produce better regulatory outcomes than organizations that have not prepared staff.
Your compliance and quality teams should train staff on how to interact with surveyors and investigators. The training should cover: how to respond to questions accurately, when to refer regulators to designated organizational contacts, and how to report surveyor interactions to the compliance team.
The healthcare delegation guide discusses how regulatory training connects to clinical operations and compliance culture.
Conclusion
A regulatory review delegation playbook ensures that healthcare organizations respond to regulatory scrutiny in an organized, legally sound, and strategically coherent way. The CEO who builds this playbook, appoints a strong CCO and GC, and maintains appropriate personal engagement in significant regulatory matters protects the organization from the most severe regulatory consequences while demonstrating to regulators the organizational commitment to compliance and quality.
Related Reading
For further context, explore Delegation Playbook for Automotive CEO: Cost Reduction and Delegation Playbook for Automotive CEO: Crisis Management.